Investigational pharmacologic treatment for liver disease

Lori L. Siatkosky; Kenneth M. Shermock; Zobair M. Younossi

doi:10.1517/13543784.11.9.1281

Investigational pharmacologic treatment for liver disease

Lori L. Siatkosky, Kenneth M. Shermock, Zobair M. Younossi

Research output: Contribution to journal › Review article › peer-review

Abstract

Liver disease can cause significant morbidity and mortality. Few pharmacological options exist for these diseases, however, new agents are in development and older agents are being evaluated for new indications. Several new nucleoside and nucleotide analogues are being developed to treat hepatitis B virus infection. Pegylated interferons have been developed for hepatitis C infection. Ursodeoxycholic acid has recently been implicated in the treatment of liver disease, including non-alcoholic steatohepatitis and primary sclerosing cholangitis.

Original language	English (US)
Pages (from-to)	1281-1293
Number of pages	13
Journal	Expert Opinion on Investigational Drugs
Volume	11
Issue number	9
DOIs	https://doi.org/10.1517/13543784.11.9.1281
State	Published - Sep 2002
Externally published	Yes

Keywords

Hepatitis B virus
Hepatitis C virus
Non-alcoholic steatohepatitis
Nucleoside analogues
Nucleotide analogues
Pegylated interferon
Primary sclerosing cholangitis
Ursodeoxycholic acid
Ursodiol

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1517/13543784.11.9.1281

Cite this

@article{70d1b2439f0e4e9dad44b68981e86154,

title = "Investigational pharmacologic treatment for liver disease",

abstract = "Liver disease can cause significant morbidity and mortality. Few pharmacological options exist for these diseases, however, new agents are in development and older agents are being evaluated for new indications. Several new nucleoside and nucleotide analogues are being developed to treat hepatitis B virus infection. Pegylated interferons have been developed for hepatitis C infection. Ursodeoxycholic acid has recently been implicated in the treatment of liver disease, including non-alcoholic steatohepatitis and primary sclerosing cholangitis.",

keywords = "Hepatitis B virus, Hepatitis C virus, Non-alcoholic steatohepatitis, Nucleoside analogues, Nucleotide analogues, Pegylated interferon, Primary sclerosing cholangitis, Ursodeoxycholic acid, Ursodiol",

author = "Siatkosky, {Lori L.} and Shermock, {Kenneth M.} and Younossi, {Zobair M.}",

year = "2002",

month = sep,

doi = "10.1517/13543784.11.9.1281",

language = "English (US)",

volume = "11",

pages = "1281--1293",

journal = "Expert Opinion on Investigational Drugs",

issn = "1354-3784",

publisher = "Taylor and Francis Ltd.",

number = "9",

}

TY - JOUR

T1 - Investigational pharmacologic treatment for liver disease

AU - Siatkosky, Lori L.

AU - Shermock, Kenneth M.

AU - Younossi, Zobair M.

PY - 2002/9

Y1 - 2002/9

N2 - Liver disease can cause significant morbidity and mortality. Few pharmacological options exist for these diseases, however, new agents are in development and older agents are being evaluated for new indications. Several new nucleoside and nucleotide analogues are being developed to treat hepatitis B virus infection. Pegylated interferons have been developed for hepatitis C infection. Ursodeoxycholic acid has recently been implicated in the treatment of liver disease, including non-alcoholic steatohepatitis and primary sclerosing cholangitis.

AB - Liver disease can cause significant morbidity and mortality. Few pharmacological options exist for these diseases, however, new agents are in development and older agents are being evaluated for new indications. Several new nucleoside and nucleotide analogues are being developed to treat hepatitis B virus infection. Pegylated interferons have been developed for hepatitis C infection. Ursodeoxycholic acid has recently been implicated in the treatment of liver disease, including non-alcoholic steatohepatitis and primary sclerosing cholangitis.

KW - Hepatitis B virus

KW - Hepatitis C virus

KW - Non-alcoholic steatohepatitis

KW - Nucleoside analogues

KW - Nucleotide analogues

KW - Pegylated interferon

KW - Primary sclerosing cholangitis

KW - Ursodeoxycholic acid

KW - Ursodiol

UR - http://www.scopus.com/inward/record.url?scp=0036736520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036736520&partnerID=8YFLogxK

U2 - 10.1517/13543784.11.9.1281

DO - 10.1517/13543784.11.9.1281

M3 - Review article

C2 - 12225249

AN - SCOPUS:0036736520

SN - 1354-3784

VL - 11

SP - 1281

EP - 1293

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

IS - 9

ER -

Investigational pharmacologic treatment for liver disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this